Fipamezole Transition from Biovail completed
Program Well Advanced Towards Phase III
21-Feb-2011 -
Santhera Pharmaceuticals announced that the transition of the fipamezole program back from Biovail was successfully completed. Fipamezole is being developed as a potential first treatment of Dyskinesia in Parkinson's Disease. During its partnership with Santhera and in preparation for Phase III ...
dyskinesia
Parkinson's disease
phase III studies
+1